BCM
KLRS

Bridgeway Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Bridgeway Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$130K Hold
22,500
– – ﹤0.01% 1096
2025
Q4 		$190K Hold
22,500
– – ﹤0.01% 1029
2025
Q3 		$130K Buy
+22,500
New +$74.4K ﹤0.01% 1075

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Bridgeway Capital Management's KLRS Position: Q1 2026 in Review

Bridgeway Capital Management held its Kalaris Therapeutics (KLRS) position steady in Q1 2026 at 22,500 shares worth $130K. The position accounts for ﹤0.01% of the portfolio, ranked #1096.

Bridgeway Capital Management first reported a position in KLRS in Q3 2025 and has held it in 3 quarters since. The position peaked at $190K in Q4 2025. 58 funds tracked by Wall St. Rank hold KLRS as of Q1 2026.

  • Bridgeway Capital Management held 22,500 shares of Kalaris Therapeutics worth $130K as of Q1 2026.
  • Bridgeway Capital Management left its Kalaris Therapeutics share count unchanged in Q1 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q1 2026, its #1096 holding.
  • Bridgeway Capital Management first reported a position in Kalaris Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Bridgeway Capital Management's Kalaris Therapeutics position peaked at $190K in Q4 2025.
  • 58 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.